A downtrend has been apparent in Inventiva S.A. Sponsored ADR (IVA) lately with too much selling pressure. The stock has declined 28% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical in ...

The first abstract demonstrates that the improvements of MACK-3, a diagnostic test for metabolic dysfunction-associated steatohepatitis, parallel the histological response to lanifibranor therapy in patients with MASH/NASH, in the NATIVE Phase IIb clinical trial.The second abstract brings additional evidence supporting the role of intrahepatic vascular alterations in the development of MASLD-related portal hypertension and the progression to MASH and highlights the potential of lanifibranor in addressing th ...

Cash and cash equivalents at €11.0 million, short-term2 deposits at €0.1million, and long-term deposit at €19.1 million3 as of March 31, 2024, compared to €26.9 million, €0.01 million and €9.0 million as of December 31, 2023, respectively.The fourth scheduled DMC meeting recommended to continue the NATiV3 Phase III clinical trial without modification of the current protocol, based on the pre-planned review of interim safety data of more than 900 patients randomized in the main and exploratory cohorts.280 si ...

The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data. The recommendation was based on the unblinded review by the DMC of safety data from more than 900 patients randomized in the main and exploratory cohorts, including more than 360 and 80 patients that have been treated for more than 48 and 72 weeks, respectively. The patient who experienced the adverse event of increased liver test results, whi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

财务数据和关键指标变化 - 公司2023年全年收入为1750万欧元,较2022年增长超过40% [17] - 2023年研发费用增加82%,达到1.1亿欧元,反映了临床试验加速 [18] - 2023年净亏损1.104亿欧元,较2022年的5430万欧元大幅增加 [19] - 2023年年初现金及等价物为6100万欧元,较2022年年初的8840万欧元减少约3000万欧元 [20][21] 各条业务线数据和关键指标变化 - 公司研发费用中85%用于Lanifibranor项目,占总费用的75% [21] 各个市场数据和关键指标变化 - 北美和欧洲患者占NATiV3试验总患者的90%,有利于试验结果质量 [14] 公司战略和发展方向及行业竞争 - 公司计划在2024年上半年完成NATiV3试验最后一例患者入组 [13][14] - 公司认为Lanifibranor有望成为下一个获批的口服NASH治疗药物 [31] - 公司计划在NATiV3试验结果后与大型制药公司合作开发Lanifibranor在欧美市场 [42][43] 管理层对经营环境和未来前景的评论 - 管理层对Lanifibranor未来前景表示乐观,认为其在NASH/MASH治疗中将发挥关键作用 [56] 问答环节重要的提问和回答 问题1 **Seamus Fernandez 提问** - 询问管理层对Lanifibranor在糖尿病NASH患者中的市场前景看法 [28] **Frederic Cren 回答** - 公司认为Lanifibranor在NASH合并2型糖尿病患者中具有优势,约40-50%NASH患者合并2型糖尿病 [29][30] 问题2 **Rami Katkhuda 提问** - 询问何时开始在美国以外地区重启患者入组 [38] **Frederic Cren 回答** - 计划从4月开始先在加拿大和欧洲重启患者入组,这两个地区占NATiV3试验患者的大部分 [39][40] 问题3 **Lucy Codrington 提问** - 询问NATiV3试验目前患者入组和筛选情况 [45][46] **Frederic Cren 回答** - 已有75%的目标患者完成入组,筛选患者数量在减少但仍有350例,主要集中在北美和欧洲 [47][48] **Jean Volatier 回答** - 公司正在与EIB保持沟通,可能在未来6个月至1年内获得新的贷款 [50]

Inventiva S.A. (NASDAQ:IVA) Q2 2023 Earnings Analyst Conference Call September 29, 2023 8:00 AM ET Company Participants Frederic Cren - CEO Jean Volatier - CFO Michael Cooreman - Chief Medical Officer Conference Call Participants Ed Arce - H.C. Wainwright Lucy Codrington - Jefferies & Co. Evan Wang - Guggenheim Securities Jacob Mekhael - KBC Securities Frederic Cren Good morning, good afternoon, everybody, and thank you for joining us on our 2023 half year financial results webcast. So you're familiar with ...

Table of Contents Exhibit 99.1 INVENTIVA S.A. A joint-stock company (société anonyme) with a share capital of 517,528.07 euros Registered office: 50, rue de Dijon, 21121 Daix, France Dijon Trade and Companies Register 537 530 255 INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2023 Table of Contents Table of contents 1. Interim Financial Report 3 1.1. General overview of activities 3 1.2. Significant events in the first half of 2023 5 1.3. Recent events and prospects 6 ...

业绩总结 - 2023年第一季度销售额达到12.2亿欧元[51] - 研发费用显著增加，预计2023年将继续增长[52] - 预计2025年下半年将获得重要数据[55] 新产品和新技术研发 - NATiV3项目在23个国家展开第三期临床试验，拥有超过350个活跃临床研究点[5] - NATiV3的新设计将更具吸引力，缩短了暴露于安慰剂的时间[19] - NATiV3的主要变化包括缩短暴露于安慰剂的时间和减少活检次数[21] 市场扩张和并购 - 与Sino Biopharm合作，获得近1300万欧元的前期付款和最高2.9亿欧元的里程碑奖励[9] - NATiV3的研究范围涵盖全球范围，包括美洲、欧洲、南非和澳大利亚[30] - 公司目前正在进行的NATiV3试验的招募情况良好，屏幕失败率在过去几个月稳步下降[81] 负面信息 - 通过欧洲投资银行交易获得近8000万欧元[53] - 公司的现金储备可支撑至2023年底，此外还有其他市场项目的资金储备[91]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...